Is AbbVie Inc. (ABBV) a Buy, Sell, or Hold?
AbbVie Inc.
NYSE:ABBV
$244.78 USD
-$3.22 (-1.3%)
- Volume
- 5.25M
- Average Volume
- 7.21M
- Market Capitalization
- $432.48B
- P/E Ratio
- 120.02
- Dividend Yield
- 2.79%
- Price Target
- $275.00
- Year High
- $261.64
- Year Low
- $184.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $3.25
- Current Ratio
- $0.80
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Robert A. Michael |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | ABBV |
| CUSIP | 00287Y109 |
| CIK | 0001551152 |
| Web | https://www.abbvie.com |
| Phone | 847 932 7900 |
| Currency | USD |
| Employees | 57000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.65 |
| Payout Ratio | 3.25 |
| Current Ratio | 0.80 |
| Quick Ratio | 0.68 |
| Cash Ratio | 0.22 |
Sales & Book Value
| Annual Sales | $61.16B |
| Price / Sales | 6.88 |
| Cash Flow | 11.76 |
| Price / Cash Flow | 20.73 |
| Price / Book | 15.79 |
Price Target and Rating
| Average Stock Price Forecast | $275.00 |
| High Stock Price Forecast | $300.00 |
| Low Stock Price Forecast | $223.00 |
| Forecast Upside/Downside | -10.99% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.37 |
| Trailing P/E Ratio | 120.02 |
| PEG Ratio | -9.10 |
| P/E Growth | -9.10 |
| Net Income | $4.23B |
| Net Margin | 5.79% |
| Pretax Margin | 9.51% |
| Return on Equity | 68.01% |
| Return on Assets | 2.67% |
Financials Score
| AltmanZ Score | 2.83 |
| Piotroski Score | 7.00 |
| Working Capital | -8.57B |
| Total Assets | 136.46B |
| Ebit | 8.88B |
| Market Cap | 438.16B |
| Total Liabilities | 108.96B |
Poll Results
About AbbVie Inc. (NYSE:ABBV) Stock
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals wi ... th chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
2026-07-14 10:30:22
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?
2026-07-14 09:04:05
VYM offers broader diversification with lower costs, while HDV is a more concentrated ETF with a heavy weightage on defensive stocks.
2026-07-14 08:05:00
SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation Debuts flagship retail experiences designed to support practice and patients' needs IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.
2026-07-14 05:00:00
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
2026-07-13 17:06:04
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors
2026-07-13 12:15:00
You need to look beyond the tech sector to find great dividend stocks for the long term.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
2026-07-11 20:15:00
AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition of Apogee helps expand its drug pipeline.
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
2026-07-10 20:24:00
On July 10, 2026, AbbVie Inc (ABBV) shares fell 0.7% to a current price of $248.08. This price is down from a 52-week high of $261.64 and remains significantly
Frequently Asked Questions
-
What is the current AbbVie Inc. (ABBV) stock price?
-
AbbVie Inc.(NYSE:ABBV) stock price is $244.78 in the last trading session. During the trading session, ABBV stock reached the peak price of $261.64 while $184.63 was the lowest point it dropped to. The percentage change in ABBV stock occurred in the recent session was --1.3% while the dollar amount for the price change in ABBV stock was -$-3.22.
-
ABBV's industry and sector of operation?
-
The NYSE listed ABBV is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of ABBV?
-
Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer
Elizabeth Shea | Senior Vice President of Investor Relations
Perry C. Siatis | Executive Vice President, General Counsel & Secretary
Wulff-Erik von Borcke | Senior Vice President & President of Oncology
Linda Ray | Senior VP & Chief Information Officer -
How many employees does ABBV have?
-
Number of ABBV employees currently stands at 57000. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.
-
Link for ABBV official website?
-
Official Website of ABBV is: https://www.abbvie.com
-
How do I contact ABBV?
-
ABBV could be contacted at phone #847 932 7900 and can also be accessed through its website. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.
-
How many shares of ABBV are traded daily?
-
The average number of ABBV shares traded daily for last 3 months was 7.21M.
-
What is the market cap of ABBV currently?
-
The market value of ABBV currently stands at $432.48B with its latest stock price at $244.78